par Eiger, Daniel;Pondé, Noam;de Azambuja, Evandro 
Référence Future oncology, 15, 16, page (1823-1843)
Publication Publié, 2019-06
Référence Future oncology, 15, 16, page (1823-1843)
Publication Publié, 2019-06
Article révisé par les pairs
| Résumé : | Although the prognosis of HER2-positive breast cancer patients has dramatically improved with modern chemotherapy and the monoclonal antibody trastuzumab, up to 31% of them will experience a recurrence in the long term. After the unprecedented benefit in overall survival with the addition of the second monoclonal antibody pertuzumab for patients with metastatic disease, the drug was tested with various degrees of success in the preoperative and postoperative settings. In this review, we will focus on the pharmacologic aspects of the drug, including mechanism of action and toxicities, and discuss clinical data regarding its use in advanced and early stage HER2-positive breast cancer, placing in perspective the pros and cons regarding other available drugs and biomarkers. |
